Skip to content

Study · Not a test of the peptide alone · 2024

1 result

Utility of a bone health clinic in bridging the osteoporosis care gap: Prescribing habit review at an academic institution.

Riley M, Crossman D, Kocis P, Hassenbein S, Fox E

PloS one18 Jul 2024Cited by 3 (Europe PMC)

PMID39024281 (opens in a new tab)PMCIDPMC11257224 (opens in a new tab)DOI10.1371/journal.pone.0307029 (opens in a new tab)PepBankPUB-39024281
Download PDFPubMedAsk about this study
Jump to 1 result

Summary

ObjectiveTo analyze osteoporosis medication prescribing trends across specialties in the context of a Bone Health Clinic.IntroductionOsteoporosis affects over 10 million adults in the US, taking a significant toll on patients and the healthcare system. Although screening methods and treatments are improving, the disease remains underdiagnosed and undertreated. This study aims to evaluate the prescribing trends of osteoporosis medication among department specialties to delineate the benefits of a bone health clinic.MethodsRetrospective data collection identified and analyzed patients within the Penn State Health system prescribed one of the following osteoporosis medications: Bisphosphonate, denosumab, romosozumab, teriparatide, abaloparatide, or raloxifene. Date range: 4/18/2016 to 4/14/2021. Data collection identified the specialty origin of prescriptions for osteoporosis medications across various medical specialties (e.g., orthopaedics, family medicine, and internal medicine).Results10,736 prescription orders were issued to patients with an average age of 68 years. Non-Hispanic Caucasian patients received 88.6% of prescriptions, followed by Asian (3.4%) and African American (2.2%). Female patients accounted for 87.8% of all prescriptions. The Bone Health Clinic under two orthopaedic providers wrote 3,619 prescriptions, averaging 361.9 prescriptions per provider per year-marking the highest rate among specialties. The clinic prescriptions constituted 33.7% of all prescriptions across specialties. Orthopaedic surgery prescribed the most denosumab, romosozumab, teriparatide, and abaloparatide prescriptions, and had the highest number of male osteoporosis patients compared to other specialties (15.6%), consequently prescribing the most male prescriptions (578).ConclusionEstablishing a bone health clinic dedicated to osteoporosis management leads to significantly higher prescription rates per provider, increased utilization of anabolic therapies compared to other specialties, and more male patients being treated-an often-neglected population in osteoporosis.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study1

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone1

In this study, Abaloparatide (Tymlos) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Abaloparatide (Tymlos).

  1. 01HumanNot a test of Abaloparatide (Tymlos) aloneObservational studyOther

    In the health system prescribing review, orthopaedic surgery issued the most abaloparatide prescriptions among specialties.

    In plain wordsIn the prescribing review, orthopaedic surgery issued more abaloparatide prescriptions than other specialties.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    IncreaseAbaloparatide prescribing by specialty
    Study

    n: not reported in source

    Comparator
    other specialties
    Outcome group
    Patterns of use · Musculoskeletal

    Source sentences

    Summary
    Orthopaedic surgery prescribed the most denosumab, romosozumab, teriparatide, and abaloparatide prescriptions
    1 context sentence
    Summary · context
    Retrospective data collection identified and analyzed patients within the Penn State Health system prescribed one of the following osteoporosis medications: Bisphosphonate, denosumab, romosozumab, teriparatide, abaloparatide, or raloxifene.

    In this study, Abaloparatide (Tymlos) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Abaloparatide (Tymlos).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:25 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.